Compare XPRO & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XPRO | ABCL |
|---|---|---|
| Founded | 1938 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 2013 | 2020 |
| Metric | XPRO | ABCL |
|---|---|---|
| Price | $15.46 | $6.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $16.00 | $8.40 |
| AVG Volume (30 Days) | 1.3M | ★ 7.4M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $522,493,000.00 | $75,128,000.00 |
| Revenue This Year | $1.86 | N/A |
| Revenue Next Year | $4.70 | $21.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 14.89 | ★ 160.56 |
| 52 Week Low | $8.24 | $2.75 |
| 52 Week High | $18.73 | $8.44 |
| Indicator | XPRO | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 54.45 | 52.74 |
| Support Level | $12.80 | $3.38 |
| Resistance Level | $17.11 | N/A |
| Average True Range (ATR) | 0.57 | 0.71 |
| MACD | 0.17 | -0.04 |
| Stochastic Oscillator | 97.77 | 43.60 |
Expro Group Holdings NV offers products and services that span the well life cycle, including well construction, well flow management, well intervention and integrity, and subsea well access. It maintains operations around the world and specializes in offshore production solutions. It also provides production optimization for both onshore and offshore applications. The company has four operating segments: North and Latin America (NLA); Europe and Sub-Saharan Africa (ESSA); Middle East and North Africa (MENA); and Asia-Pacific (APAC). The majority of its revenue is derived from the North and Latin America (NLA) segment.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.